• Corpus ID: 39058679

FLT 3 , RAS , and TP 53 mutations in elderly patients with acute myeloid leukemia

@inproceedings{Stirewalt2001FLT3,
  title={FLT 3 , RAS , and TP 53 mutations in elderly patients with acute myeloid leukemia},
  author={Derek L Stirewalt and Kenneth J. Kopecky and Soheil Meshinchi and Frederick R. Appelbaum and Marilyn L. Slovak and Cheryl Willman and Jerald P Radich},
  year={2001}
}
The prevalence and significance of genetic abnormalities in older patients with acute myeloid leukemia (AML) are unknown. Polymerase chain reactions and single-stranded conformational polymorphism analyses were used to examine 140 elderly AML patients enrolled in the Southwest Oncology Group study 9031 for FLT3, RAS, and TP53 mutations, which were found in 34%, 19%, and 9% of patients, respectively. All but one of the FLT3 (46 of 47) mutations were internal tandem duplications (ITDs) within… 

Figures and Tables from this paper

RAS, FLT3, and TP53 mutations in therapy‐related myeloid malignancies with abnormalities of chromosomes 5 and 7
Oncogenic mutations in the KRAS2, NRAS, or FLT3 gene are detected in more than 50% of patients with de novo acute myeloid leukemia (AML). RAS mutations are also prevalent in de novo myelodysplastic
Implications of NRAS mutations in AML: a study of 2502 patients.
TLDR
There was a trend to better survival in most subgroups, especially when other molecular markers (FLT3-LM, MLL-PTD, and NPM) were taken into account, and there was a significant prognostic impact of NRAS(mut) for overall survival, event- free survival, and disease-free survival.
FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India
TLDR
Distinct prognostic subclasses of adult AML patients were identified based on the presence of NPM1 and FLT3 mutations, showing distinct correlations with hematologic, immunophenotypic, cytogenetics characteristics and follow-up.
Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3
TLDR
This validated panel now provides an important tool to evaluate other candidate genes in the genesis of myeloid malignancy as well as identify new novel recurring gene mutations in AML.
Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy
TLDR
The results suggest that the bad prognosis associated withFLT3-ITDs in AML might be partly overcome using reinforced chemotherapy, and early detection of FLT3 mutations might thus be useful to intensify induction as well as post-remission therapy in FLT2-ITD patients.
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
TLDR
Mutational profiling of 14 genes previously implicated in leukemogenesis using 14 MDS/leukemia samples from patients with SCN supports the hypothesis that mutations of CSF3R may provide the "activated tyrosine kinase signal" that is thought to be important for leukeMogenesis.
Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients
TLDR
The frequency and clinical relevance of FLT3 abnormalities were ascertained in a cohort of elderly AML patients in the hope of determining the prognostic significance of these alterations among the elderly.
Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor
TLDR
Investigation of the inhibitory effects of AG1296 on FLT3/ITDs isolated from AML patients in the IL-3-dependent cell line, Ba/F3, as well as in primary leukemia samples fromAML patients, suggest that inhibiting the activity ofFLT3 may have a therapeutic value in some leukemias expressing FLT 3/ ITDs.
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
  • M. Levis
  • Biology, Medicine
    Hematology. American Society of Hematology. Education Program
  • 2013
TLDR
The preponderance of evidence suggests that transplantation in first remission, if possible, is probably the best option and Clinically useful FLT3 inhibitors are hopefully on the near horizon and are being studied in the context of current treatment paradigms.
...
1
2
3
4
...

References

SHOWING 1-10 OF 48 REFERENCES
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
TLDR
The FLT3 gene mutation, whose presence is detectable only by genomic polymerase chain reaction amplification and gel electrophoresis, might serve as an important molecular marker to predict the prognosis of patients with AML.
N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance.
TLDR
A comparison of patients with and without N-ras mutations showed no statistically significant differences in pretreatment clinical variables, response to induction therapy, or survival, except for a possibly higher percentage of FAB M4 subtypes in patients with the N-ra mutation.
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies.
TLDR
P53 mutations could induce drug resistance, at least in part, by interfering with normal apoptotic pathways in tumor cells, and are a strong prognostic indicator of response to chemotherapy and survival in AML, MDS, and CLL.
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia
TLDR
Findings counter the prevailing bias that oncogene mutations lead to more aggressive behavior in human malignancies and suggest a longer survival in ras-positive patients.
Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia.
TLDR
FLT3/ITD was observed in 11% of childhood AML and identified to be associated with poor prognosis and a large prospective study with uniform treatment is necessary to confirm the results.
Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene
TLDR
Data show that the Flt3/ITD represents an important diagnostic marker for patient prognosis, and that the presence of these mutations is associated with altered proliferative ability of progenitors in vivo and in vitro.
Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia
TLDR
The results suggest that the tandem duplication in the jm domain of the FLT3 gene is not a frequent phenomenon but might be a factor of poor prognosis in childhood patients with AML.
Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia
TLDR
The fact that the accumulation of genetic events, including FLT3 duplication, correlates with leukemic transformation from antecedent myelodysplasia and with subsequent disease progression is uncovered.
N-ras Mutations in Acute Myelogenous Leukemia: A Review of the Current Literature and an update of the Southwest Oncology Group Experience
TLDR
The SWOG study examined 55 adult AML patients prospectively enrolled in a treatment protocol and found N-ras point mutations in 8 of 55 patients, except for a higher percentage of FAB M4 subtypes among mutation-positive patients.
P53 gene mutations in acute myeloid leukemia with 17p monosomy.
TLDR
The fact that P53 gene mutations occurred more often in patients with 17p monosomy seems to support the "recessive" model of tumor suppressive activity of the P53 genes rather than the "dominant" model, in which alteration of only one allele is sufficient for the development of malignancy.
...
1
2
3
4
5
...